title: Minor structural modifications convert a selective PPARalpha agonist into a potent, highly selective PPARdelta agonist.
abstract: We report the solid-phase synthesis and pharmacological evaluation of a new series of small-molecule agonists of the human peroxisome proliferator-activated receptor delta (PPARdelta) based on a lead structure from our PPARalpha program. Compound 33 showed good pharmacokinetics.
authors.affiliation: BAYER Health Care AG, Pharma Research, D-42096 Wuppertal, Germany. stefan.weigand@roche.com
authors.forename: Stefan
authors.initials: S
authors.lastname: Weigand
authors.forename: Hilmar
authors.initials: H
authors.lastname: Bischoff
authors.forename: Elke
authors.initials: E
authors.lastname: Dittrich-Wengenroth
authors.forename: Heike
authors.initials: H
authors.lastname: Heckroth
authors.forename: Dieter
authors.initials: D
authors.lastname: Lang
authors.forename: Andrea
authors.initials: A
authors.lastname: Vaupel
authors.forename: Michael
authors.initials: M
authors.lastname: Woltering
mesh_terms: D047493:PPAR alpha / Q000819:agonists*; D047494:PPAR delta / Q000819:agonists*; D013329:Structure-Activity Relationship
chemical_list: D047493:PPAR alpha; D047494:PPAR delta